IBDEI1NJ ; ; 04-FEB-2020
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,26378,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,26378,1,3,0)
 ;;=3^DM Type 1 w/o Compl
 ;;^UTILITY(U,$J,358.3,26378,1,4,0)
 ;;=4^E10.9
 ;;^UTILITY(U,$J,358.3,26378,2)
 ;;=^5002626
 ;;^UTILITY(U,$J,358.3,26379,0)
 ;;=E10.620^^107^1240^5
 ;;^UTILITY(U,$J,358.3,26379,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,26379,1,3,0)
 ;;=3^DM Type 1 w/ Diab Dermatitis
 ;;^UTILITY(U,$J,358.3,26379,1,4,0)
 ;;=4^E10.620
 ;;^UTILITY(U,$J,358.3,26379,2)
 ;;=^5002615
 ;;^UTILITY(U,$J,358.3,26380,0)
 ;;=E10.36^^107^1240^4
 ;;^UTILITY(U,$J,358.3,26380,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,26380,1,3,0)
 ;;=3^DM Type 1 w/ Diab Cataract
 ;;^UTILITY(U,$J,358.3,26380,1,4,0)
 ;;=4^E10.36
 ;;^UTILITY(U,$J,358.3,26380,2)
 ;;=^5002602
 ;;^UTILITY(U,$J,358.3,26381,0)
 ;;=E10.621^^107^1240^6
 ;;^UTILITY(U,$J,358.3,26381,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,26381,1,3,0)
 ;;=3^DM Type 1 w/ Diab Foot Ulcer
 ;;^UTILITY(U,$J,358.3,26381,1,4,0)
 ;;=4^E10.621
 ;;^UTILITY(U,$J,358.3,26381,2)
 ;;=^5002616
 ;;^UTILITY(U,$J,358.3,26382,0)
 ;;=E10.622^^107^1240^28
 ;;^UTILITY(U,$J,358.3,26382,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,26382,1,3,0)
 ;;=3^DM Type 1 w/ Oth Skin Ulcer
 ;;^UTILITY(U,$J,358.3,26382,1,4,0)
 ;;=4^E10.622
 ;;^UTILITY(U,$J,358.3,26382,2)
 ;;=^5002617
 ;;^UTILITY(U,$J,358.3,26383,0)
 ;;=E10.51^^107^1240^32
 ;;^UTILITY(U,$J,358.3,26383,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,26383,1,3,0)
 ;;=3^DM Type 1 w/ Periph Angiopathy w/o Gangrene
 ;;^UTILITY(U,$J,358.3,26383,1,4,0)
 ;;=4^E10.51
 ;;^UTILITY(U,$J,358.3,26383,2)
 ;;=^5002610
 ;;^UTILITY(U,$J,358.3,26384,0)
 ;;=E10.52^^107^1240^31
 ;;^UTILITY(U,$J,358.3,26384,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,26384,1,3,0)
 ;;=3^DM Type 1 w/ Periph Angiopathy w/ Gangrene
 ;;^UTILITY(U,$J,358.3,26384,1,4,0)
 ;;=4^E10.52
 ;;^UTILITY(U,$J,358.3,26384,2)
 ;;=^5002611
 ;;^UTILITY(U,$J,358.3,26385,0)
 ;;=E11.00^^107^1241^19
 ;;^UTILITY(U,$J,358.3,26385,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,26385,1,3,0)
 ;;=3^DM Type 2 w/ Hyperosmolarity w/o NKHHC
 ;;^UTILITY(U,$J,358.3,26385,1,4,0)
 ;;=4^E11.00
 ;;^UTILITY(U,$J,358.3,26385,2)
 ;;=^5002627
 ;;^UTILITY(U,$J,358.3,26386,0)
 ;;=E11.01^^107^1241^18
 ;;^UTILITY(U,$J,358.3,26386,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,26386,1,3,0)
 ;;=3^DM Type 2 w/ Hyperosmolarity w/ Coma
 ;;^UTILITY(U,$J,358.3,26386,1,4,0)
 ;;=4^E11.01
 ;;^UTILITY(U,$J,358.3,26386,2)
 ;;=^5002628
 ;;^UTILITY(U,$J,358.3,26387,0)
 ;;=E11.21^^107^1241^7
 ;;^UTILITY(U,$J,358.3,26387,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,26387,1,3,0)
 ;;=3^DM Type 2 w/ Diab Nephropathy
 ;;^UTILITY(U,$J,358.3,26387,1,4,0)
 ;;=4^E11.21
 ;;^UTILITY(U,$J,358.3,26387,2)
 ;;=^5002629
 ;;^UTILITY(U,$J,358.3,26388,0)
 ;;=E11.22^^107^1241^3
 ;;^UTILITY(U,$J,358.3,26388,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,26388,1,3,0)
 ;;=3^DM Type 2 w/ Diab CKD
 ;;^UTILITY(U,$J,358.3,26388,1,4,0)
 ;;=4^E11.22
 ;;^UTILITY(U,$J,358.3,26388,2)
 ;;=^5002630
 ;;^UTILITY(U,$J,358.3,26389,0)
 ;;=E11.39^^107^1241^28
 ;;^UTILITY(U,$J,358.3,26389,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,26389,1,3,0)
 ;;=3^DM Type 2 w/ Oth Diab Ophth Compl
 ;;^UTILITY(U,$J,358.3,26389,1,4,0)
 ;;=4^E11.39
 ;;^UTILITY(U,$J,358.3,26389,2)
 ;;=^5002643
 ;;^UTILITY(U,$J,358.3,26390,0)
 ;;=E11.41^^107^1241^6
 ;;^UTILITY(U,$J,358.3,26390,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,26390,1,3,0)
 ;;=3^DM Type 2 w/ Diab Mononeuropathy
